On (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

Cartesian reports 12-month data for Descartes-08 in myasthenia gravis; Phase 3 AURORA trial expected to begin in Q2 2025.

Interim results from the ME&MGopen study demonstrate strong adherence, high usability, and meaningful clinical associations in myasthenia ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...

Cartesian Therapeutics reports sustained benefits of Descartes-08 CAR-T therapy in generalized myasthenia gravis patients, ...

MG-ADL (Myasthenia Gravis - Activities of Daily Living) provides a rapid clinical assessment of the patient's recall of symptoms impacting activities of daily living, with a total score range of 0 to ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, ...

Advances Amgen’s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, CA, USA I April 3, 2025 I Amgen (NASDAQ:AMGN) ...

UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome ...